NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor Conferences. Details of the company’s participation are as follows: A webcast will be available on atai’s website under Events on the Investors section of…

Source

Previous articleAlgernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
Next articleNuminus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023